Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics presents preclinical data on MRT-8102
- Monte Rosa Therapeutics Reports Strong Revenue Growth
- Monte Rosa Therapeutics: Promising Advancements and Financial Stability Drive Buy Rating
- Monte Rosa Therapeutics: Strategic Partnerships and Growth Potential Justify Buy Rating
- Monte Rosa Announces Q3 Results and Novartis Collaboration